Filing Flows › Nuvation Bio (NUVB) › Q2 2026 › vs Q2 2025
Nuvation Bio (NUVB) Q2 2026 vs Q2 2025 (year over year)
Nuvation Bio's revenue rose $26.9M (+556%) from $4.8M in Q2 2025 to $31.7M in Q2 2026. The biggest changes: License +$4.9M (+136%).
Nuvation Bio, Q2 2026: revenue $31.7M (+556% year over year), operating margin -161.1%, net loss $62.8M, operating cash flow −$43.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| License | $8.5M | $3.6M | $4.9M | +136% |
| Revenue | $31.7M | $4.8M | $26.9M | +556% |
| Net loss | $62.8M | $59.0M | $3.8M | +6% |
| Costs & expenses | $94.5M | $68.4M | $26.1M | +38% |
| Operating costs | $82.7M | $68.4M | $14.3M | +21% |
| Interest & other, net | $11.8M | −$4.6M | $16.4M | — |
| Research & development | $30.7M | $27.4M | $3.3M | +12% |
| SG&A | $42.6M | $38.5M | $4.1M | +11% |
| Operating cash sources | $62.8M | $59.0M | $3.8M | +6% |
| Depreciation & amortization | $536K | $356K | $180K | +51% |
| Share-based compensation | $10.5M | $12.0M | −$1.6M | -13% |
| Working capital & other | $8.9M | −$1.6M | $10.4M | — |
| Cash used in operations | $43.0M | $48.2M | −$5.2M | -11% |
| Net loss absorbed | $62.8M | $59.0M | $3.8M | +6% |
Questions
How much did Nuvation Bio's revenue grow year over year in Q2 2026?
Nuvation Bio's revenue rose $26.9M (+556%) from $4.8M in Q2 2025 to $31.7M in Q2 2026.
What drove Nuvation Bio's revenue change in Q2 2026?
License +$4.9M (+136%).